VanEck Pharmaceutical ETF vs. Invesco Biotech ETF: Which Fund Fits Your Investing Style?

Sarah Sidlow, The Motley Fool

Wed, August 12, 2026 astatine 12:08 PM CDT 4 min read

VanEck Pharmaceutical ETF (NASDAQ:PPH) provides lower-cost vulnerability to established cause manufacturers with little humanities volatility, portion Invesco Biotechnology & Genome ETF (NYSEMKT:PBE) targets high-growth biotech companies astatine a higher expense.

These 2 healthcare funds connection chiseled ways to play the beingness sciences sector. While the VanEck money concentrates connected large pharmaceutical giants, the Invesco money focuses connected companies successful the biotech and genomic space, selecting them based connected factors similar net maturation and terms momentum.

Snapshot (cost & size)

Beta measures terms volatility comparative to the S&P 500; beta is calculated from monthly returns implicit the disposable money past (up to 5 years). The 1-yr instrumentality represents full instrumentality implicit the trailing 12 months. Dividend output is the trailing-12-month organisation yield.

Cost-conscious investors whitethorn similar the VanEck Pharmaceutical ETF, which has an disbursal ratio of 0.36%. This is notably much affordable than the 0.58% charged by the Invesco Biotechnology & Genome ETF. Additionally, the VanEck money offers a higher trailing-12-month dividend payout.

Performance & hazard examination

What's wrong

VanEck Pharmaceutical ETF tracks the wide show of 27 companies progressive successful pharmaceutical research, development, and sales. Its largest positions see Eli Lilly & Co astatine 20.17%, Novartis Ag astatine 10.32%, and Merck & Co. astatine 9.74%. The money was launched successful 2011. VanEck Pharmaceutical ETF has paid $2.17 per stock implicit the trailing 12 months, which connected its caller ~$112.74 stock terms works retired to a 1.9% yield.

Invesco Biotechnology & Genome ETF focuses connected 31 U.S. companies that it selects based connected factors similar momentum, net growth, and absorption quality. Its largest positions see Regeneron Pharmaceuticals at 5.5%, Amgen Inc astatine 5.36%, and Vertex Pharmaceuticals astatine 5.2%. The money was launched successful 2005. Invesco Biotechnology & Genome ETF has paid $1.55 per stock implicit the trailing 12 months, which connected its caller ~$93.84 stock terms works retired to a 1.6% yield.

For much guidance connected ETF investing, cheque retired the afloat usher astatine this link.